

# Stanford

---



## R. Jeremy Nichols

Sr Res Scientist, Pathology - Montine Lab

### Bio

---

#### EDUCATION AND CERTIFICATIONS

- Post-doc, MRC Protein Phosphorylation Unit , Signal Transduction (2010)
- PhD, Medical College of Wisconsin , kinases & molecular genetics (2006)
- BS, Austin Peay State University , Biology (2000)

### Professional

---

#### WORK EXPERIENCE

- Senior Research Scientist - Stanford University (8/1/2018 - present)

### Publications

---

#### PUBLICATIONS

- **Targeting LRRK2 mutations in Parkinson's disease.** *Future medicinal chemistry*  
Leśniak, R. K., Nichols, R. J., Smith, M., Montine, T. J.  
2022
- **Discovery of 1H-Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase Inhibitors.** *ACS medicinal chemistry letters*  
Lesniak, R. K., Nichols, R. J., Schonemann, M., Zhao, J., Gajera, C. R., Lam, G., Nguyen, K. C., Langston, J. W., Smith, M., Montine, T. J.  
2022; 13 (6): 981-988
- **Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity.** *Journal of Parkinson's disease*  
Fernandez, B., Chittoor-Vinod, V. G., Kluss, J. H., Kelly, K., Bryant, N., Nguyen, A. P., Bukhari, S. A., Smith, N., Lara Ordonez, A. J., Fdez, E., Chartier-Harlin, M., Montine, T. J., Wilson, et al  
2022
- **The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity.** *The Journal of cell biology*  
Stormo, A. E., Shavarebi, F., FitzGibbon, M., Earley, E. M., Ahrendt, H., Lum, L. S., Verschuere, E., Swaney, D. L., Skibinski, G., Ravisankar, A., van Haren, J., Davis, E. J., Johnson, et al  
2022; 221 (4)
- **A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively.** *Cells*  
Marchand, A., Sarchione, A., Athanasopoulos, P. S., Roy, H. B., Goveas, L., Magnez, R., Drouyer, M., Emanuele, M., Ho, F. Y., Liberelle, M., Melnyk, P., Lebegue, N., Thuru, et al  
2022; 11 (6)
- **The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.** *Brain research*  
Cogo, S., Ho, F. Y., Tosoni, E., Tomkins, J. E., Tessari, I., Iannotta, L., Montine, T. J., Manzoni, C., Lewis, P. A., Bubacco, L., Chartier Harlin, M., Taymans, J., Kortholt, et al

1800: 147781

- **Editorial: LRRK2-Fifteen Years From Cloning to the Clinic.** *Frontiers in neuroscience*  
Rideout, H., Greggio, E., Kortholt, A., Nichols, R. J.  
2022; 16: 880914
- **Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with invivo efficacy.** *European journal of medicinal chemistry*  
Lesniak, R. K., Nichols, R. J., Schonemann, M., Zhao, J., Gajera, C. R., Fitch, W. L., Lam, G., Nguyen, K. C., Smith, M., Montine, T. J.  
1800; 229: 114080
- **Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation.** *Neurobiology of disease*  
Drouyer, M., Bolliger, M. F., Lobbstaël, E., Van den Haute, C., Emanuele, M., Lefebvre, R., Sibrán, W., De Wit, T., Leghay, C., Mutez, E., Dzamko, N., Halliday, G. M., Murayama, et al  
2021: 105426
- **Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism.** *International journal of molecular sciences*  
Chittoor-Vinod, V. G., Nichols, R. J., Schule, B.  
2021; 22 (3)
- **Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics.** *The Journal of biological chemistry*  
Wu, C., Liao, J., Park, Y., Reed, X., Engel, V. A., Hoang, N. C., Takagi, Y., Johnson, S. M., Wang, M., Federici, M., Nichols, R. J., Sanishvili, R., Cookson, et al  
2019
- **LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.** *Movement disorders : official journal of the Movement Disorder Society*  
Atashrazm, F., Hammond, D., Perera, G., Bolliger, M. F., Matar, E., Halliday, G. M., Schule, B., Lewis, S. J., Nichols, R. J., Dzamko, N.  
2018
- **P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.** *The Biochemical journal*  
Kalogeropoulou, A. F., Zhao, J., Bolliger, M. F., Memou, A., Narasimha, S., Molitor, T. P., Wilson, W. H., Rideout, H. J., Nichols, R. J.  
2018; 475 (7): 1271-1293
- **Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.** *Brain : a journal of neurology*  
Zhao, Y., Perera, G., Takahashi-Fujigasaki, J., Mash, D. C., Vonsattel, J. P., Uchino, A., Hasegawa, K., Jeremy Nichols, R., Holton, J. L., Murayama, S., Dzamko, N., Halliday, G. M.  
2018; 141 (2): 486-495
- **LRRK2 Phosphorylation.** *Advances in neurobiology*  
Nichols, R. J.  
2017; 14: 51-70
- **LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.** *Movement disorders : official journal of the Movement Disorder Society*  
Dzamko, N., Gysbers, A. M., Bandopadhyay, R., Bolliger, M. F., Uchino, A., Zhao, Y., Takao, M., Wauters, S., van de Berg, W. D., Takahashi-Fujigasaki, J., Nichols, R. J., Holton, J. L., Murayama, et al  
2017; 32 (3): 423-432
- **Multisystem Lewy body disease and the other parkinsonian disorders** *NATURE GENETICS*  
Langston, J., Schuele, B., Rees, L., Nichols, R., Barlow, C.  
2015; 47 (12): 1378-84
- **LRRK2 dephosphorylation increases its ubiquitination.** *The Biochemical journal*  
Zhao, J., Molitor, T. P., Langston, J. W., Nichols, R. J.  
2015; 469 (1): 107-20
- **LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status.** *Frontiers in molecular neuroscience*  
Reynolds, A., Doggett, E. A., Riddle, S. M., Lebakken, C. S., Nichols, R. J.  
2014; 7: 54

- **Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain.** *Proceedings of the National Academy of Sciences of the United States of America*  
Liao, J., Wu, C. X., Burlak, C., Zhang, S., Sahm, H., Wang, M., Zhang, Z. Y., Vogel, K. W., Federici, M., Riddle, S. M., Nichols, R. J., Liu, D., Cookson, et al  
2014; 111 (11): 4055-60
- **Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.** *The Biochemical journal*  
Lobbestael, E., Zhao, J., Rudenko, I. N., Beylina, A., Gao, F., Wetter, J., Beullens, M., Bollen, M., Cookson, M. R., Baekelandt, V., Nichols, R. J., Taymans, J. M.  
2013; 456 (1): 119-28
- **Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.** *Biochemical Society transactions*  
Zhao, J., Hermanson, S. B., Carlson, C. B., Riddle, S. M., Vogel, K. W., Bi, K., Nichols, R. J.  
2012; 40 (5): 1158-62
- **Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.** *PloS one*  
Hermanson, S. B., Carlson, C. B., Riddle, S. M., Zhao, J., Vogel, K. W., Nichols, R. J., Bi, K.  
2012; 7 (8): e43580
- **Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.** *Journal of neurochemistry*  
Doggett, E. A., Zhao, J., Mork, C. N., Hu, D., Nichols, R. J.  
2012; 120 (1): 37-45
- **14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.** *The Biochemical journal*  
Nichols, R. J., Dzamko, N., Morrice, N. A., Campbell, D. G., Deak, M., Ordureau, A., Macartney, T., Tong, Y., Shen, J., Prescott, A. R., Alessi, D. R.  
2010; 430 (3): 393-404
- **Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.** *The Biochemical journal*  
Dzamko, N., Deak, M., Hentati, F., Reith, A. D., Prescott, A. R., Alessi, D. R., Nichols, R. J.  
2010; 430 (3): 405-13
- **Mice deficient in the serine/threonine protein kinase VRK1 are infertile due to a progressive loss of spermatogonia.** *Biology of reproduction*  
Wiebe, M. S., Nichols, R. J., Molitor, T. P., Lindgren, J. K., Traktman, P.  
2010; 82 (1): 182-93
- **Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.** *The Biochemical journal*  
Nichols, R. J., Dzamko, N., Hutti, J. E., Cantley, L. C., Deak, M., Moran, J., Bamborough, P., Reith, A. D., Alessi, D. R.  
2009; 424 (1): 47-60
- **Functional characterization of the vaccinia virus I5 protein.** *Virology journal*  
Unger, B., Nichols, R. J., Stanitsa, E. S., Traktman, P.  
2008; 5: 148
- **The vaccinia virus gene I2L encodes a membrane protein with an essential role in virion entry.** *Journal of virology*  
Nichols, R. J., Stanitsa, E., Unger, B., Traktman, P.  
2008; 82 (20): 10247-61
- **LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.** *The Biochemical journal*  
Jaleel, M., Nichols, R. J., Deak, M., Campbell, D. G., Gillardon, F., Knebel, A., Alessi, D. R.  
2007; 405 (2): 307-17
- **The vaccinia-related kinases phosphorylate the N' terminus of BAF, regulating its interaction with DNA and its retention in the nucleus.** *Molecular biology of the cell*  
Nichols, R. J., Wiebe, M. S., Traktman, P.  
2006; 17 (5): 2451-64
- **Characterization of three paralogous members of the Mammalian vaccinia related kinase family.** *The Journal of biological chemistry*  
Nichols, R. J., Traktman, P.  
2004; 279 (9): 7934-46